• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home 2MM Trial Briefs

Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial

by2 Minute MedicineandReviewed by Marc Succi, MD (Harvard Medical School)
October 25, 2026
in 2MM Trial Briefs, Gastroenterology, Oncology, Pharma
Reading Time: 2 mins read
An illustration of the pancreas, highlighting cancer cells related to pancreatic cancer and molecular structures, indicating targeted research in oncology.
Share on FacebookShare on TwitterShare on LinkedIn

1. Camupepimut did not meet the primary disease-free survival endpoint versus standard-of-care observation: median 23.8 versus 21.2 months; HR 0.85, P = 0.5329.

2. Grade ≥3 adverse events occurred in 10.4% with camupepimut and 14.6% with observation; overall survival data were not mature.

Evidence Rating Level: 2 (Good)

2MM Brief: Pancreatic ductal adenocarcinoma frequently recurs after locoregional treatment, and the AMPLIFY-7P trial evaluated a lymph node-targeted vaccine for patients with KRAS-mutated disease. George and colleagues conducted an open-label, randomized phase 2 trial in 144 adults with stage I-III pancreatic adenocarcinoma who had undergone standard locoregional therapy and had no radiographic recurrence within 6 months. Participants were randomized 2:1 to camupepimut (ELI-002 7P; n = 96) or standard-of-care observation (n = 48), with a median follow-up of 19.4 months. The primary investigator-assessed disease-free survival endpoint was not met: median disease-free survival was 23.8 months with camupepimut versus 21.2 months with observation (HR 0.85, P = 0.5329); a confidence interval was not reported in the abstract. A prespecified analysis during the dosing period showed 6-month disease-free survival of 75.7% versus 61.7%, with HR 0.55 and P = 0.0557. A post hoc multivariate analysis suggested improved disease-free survival with camupepimut (adjusted HR 0.47, P = 0.0086), while stage III disease, elevated baseline CA19-9 and baseline circulating tumor DNA positivity were associated with worse outcomes. In an exploratory analysis, 98.9% (89/90) of evaluable patients developed ex vivo mKRAS-specific T-cell responses, and responses greater than 9.17-fold over baseline correlated with improved disease-free survival (HR 0.22, P < 0.0001); these immune-response analyses were not randomized treatment comparisons. Grade ≥3 adverse events occurred in 10.4% (10/96) of camupepimut-treated patients and 14.6% (7/48) of observation patients, while serious adverse events occurred in 6.3% (6/96) and 8.3% (4/48), respectively. Overall survival data were not mature, and tumor biomarker and crossover analyses were ongoing. The trial was open-label, and several favorable analyses were post hoc or exploratory. These findings do not establish a disease-free survival benefit for camupepimut, although the reported immunogenicity and exploratory signals may inform further study.

Click here to read the study in Nature Medicine

FDA approvedFor pancreatic cancer: Rasonque (daraxonrasib), Aug 26, 2026→

Citation: George B, Singh H, Devoe CE, Chung V, Hosein PJ, Hendifar A, et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Nat Med. 2026 Oct 23. doi: 10.1038/s41591-026-04734-7. Epub ahead of print. PMID: 42919966.

© 2026 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: © 2 Minute Medicine

RELATED REPORTS

Routine CT scans show steeper fat loss years before pancreatic cancer diagnosis

Daraxonrasib extends survival in metastatic pancreatic cancer

Tags: AMPLIFY-7PCamupepimutCancer vaccineKRASpancreatic cancer
Previous Post

An electronic health record tool for exercise prescription may reduce fall rate among older adults

Next Post

Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in final phase 3 results

RelatedReports

A stylized illustration featuring the pancreas and kidney, with visual elements suggesting pain and chemotherapy effects, related to pancreatic cancer treatment.
Artificial Intelligence

Routine CT scans show steeper fat loss years before pancreatic cancer diagnosis

October 30, 2026
The image features a woman examining samples under a microscope, representations of cancer cells, a knee joint, and a liver with a pill at the center, suggesting a focus on oncology and pharmaceutical therapy.
Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
A variety of pharmaceutical items including a vial, capsule, molecule model, pill blister pack, petri dish with a pipette, and a graph, symbolizing drug development.
Pharma Roundup

2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome

September 15, 2026
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Weekly Rewinds

2 Minute Medicine Rewind July 13, 2026

July 13, 2026
Next Post
Illustration showing the lungs with a tumor, a vial representing medication, and surgical tools, indicating lung cancer treatment involving toripalimab.

Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in final phase 3 results

An illustration showing human lungs, a tray with sampling devices, and a teal awareness ribbon, representing lung cancer diagnostics and lymph node sampling.

Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer in interim phase 3 results

An abstract representation of therapeutic pathways and personal journeys towards mental health improvement, with visual elements suggesting anxiety or panic states.

2 Minute Medicine Rewind October 26, 2026

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind November 16, 2026
  • ERX1000 plus semaglutide increased weight loss and metabolic measures in diet-induced obese mice
  • Investigational retatrutide reduced knee osteoarthritis pain and body weight versus placebo in adults with obesity
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.